BlackRock’s Ensysce Biosciences ENSC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $19 | Hold |
65
| – | – | ﹤0.01% | 5659 |
|
|
2026
Q1 | $35 | Hold |
65
| – | – | ﹤0.01% | 5639 |
|
|
2025
Q4 | $60 | Hold |
65
| – | – | ﹤0.01% | 5484 |
|
|
2025
Q3 | $154 | Hold |
65
| – | – | ﹤0.01% | 5393 |
|
|
2025
Q2 | $145 | Hold |
65
| – | – | ﹤0.01% | 5405 |
|
|
2025
Q1 | $166 | Buy |
65
+1
| +2% | +$6 | ﹤0.01% | 5373 |
|
|
2024
Q4 | $521 | Sell |
64
-1
| -2% | -$7 | ﹤0.01% | 5326 |
|
|
2024
Q3 | $234 | Hold |
65
| – | – | ﹤0.01% | 5173 |
|
|
2024
Q2 | $494 | Hold |
65
| – | – | ﹤0.01% | 5219 |
|
|
2024
Q1 | $770 | Hold |
65
| – | – | ﹤0.01% | 5212 |
|
|
2023
Q4 | $1.03K | Hold |
65
| – | – | ﹤0.01% | 5267 |
|
|
2023
Q3 | $1.35K | Hold |
65
| – | – | ﹤0.01% | 5314 |
|
|
2023
Q2 | $1.75K | Hold |
65
| – | – | ﹤0.01% | 5376 |
|
|
2023
Q1 | $4.74K | Hold |
65
| – | – | ﹤0.01% | 5375 |
|
|
2022
Q4 | $8.78K | Hold |
65
| – | – | ﹤0.01% | 5479 |
|
|
2022
Q3 | $50K | Hold |
65
| – | – | ﹤0.01% | 5351 |
|
|
2022
Q2 | $203K | Hold |
65
| – | – | ﹤0.01% | 5021 |
|
|
2022
Q1 | $267K | Buy |
+65
| New | +$430K | ﹤0.01% | 5039 |
|
|
2021
Q4 | – | Hold |
0
| – | – | – | 5675 |
|
Other funds holding ENSC
BlackRock's ENSC Position: Q2 2026 in Review
BlackRock held its Ensysce Biosciences (ENSC) position steady in Q2 2026 at 65 shares worth $19. The position accounts for ﹤0.01% of the portfolio, ranked #5659.
BlackRock first reported a position in ENSC in Q1 2022 and has held it in 18 quarters since. The position peaked at $267K in Q1 2022. 3 funds tracked by Wall St. Rank hold ENSC as of Q2 2026.
- BlackRock held 65 shares of Ensysce Biosciences worth $19 as of Q2 2026.
- BlackRock left its Ensysce Biosciences share count unchanged in Q2 2026.
- Ensysce Biosciences made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #5659 holding.
- BlackRock first reported a position in Ensysce Biosciences in Q1 2022 and has held it in 18 quarters since.
- BlackRock's Ensysce Biosciences position peaked at $267K in Q1 2022.
- 3 funds tracked by Wall St. Rank held Ensysce Biosciences as of Q2 2026.
Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.